{"id":80782,"date":"2026-06-10T13:20:44","date_gmt":"2026-06-10T13:20:44","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/80782\/"},"modified":"2026-06-10T13:20:44","modified_gmt":"2026-06-10T13:20:44","slug":"roche-pharmaceuticals-ceo-bill-anderson-to-step-down","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/80782\/","title":{"rendered":"Roche pharmaceuticals CEO Bill Anderson to step down"},"content":{"rendered":"<p>Roche announced Monday that Bill Anderson, CEO of its pharmaceuticals division, will step down after nearly four years at the helm.<\/p>\n<p>His last day will be Dec. 31, Roche said, as Anderson leaves to \u201cpursue opportunities outside of Roche.\u201d A successor will be appointed by March, the company added.\u00a0<\/p>\n<p>Anderson\u2019s departure comes at the end of a rocky year for the Swiss drugmaker. The company watched two of its most closely watched candidates fail to yield results in late-stage trials: An experimental amyloid-clearing antibody <a href=\"https:\/\/www.statnews.com\/2022\/11\/14\/roches-experimental-alzheimers-treatment-fails-to-slow-cognitive-decline-across-two-clinical-trials\/\" rel=\"nofollow noopener\" target=\"_blank\">failed<\/a> to slow Alzheimer\u2019s patients\u2019 cognitive decline, and an experimental antibody for a new, highly anticipated, immuno-oncology target called TIGIT <a href=\"https:\/\/www.statnews.com\/2022\/05\/11\/roche-anti-tigit-cancer-immunotherapy-fails-second-clinical-trial\/\" rel=\"nofollow noopener\" target=\"_blank\">failed<\/a> to slow tumor growth in two different cancers.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/1781097644_968_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche announced Monday that Bill Anderson, CEO of its pharmaceuticals division, will step down after nearly four years&hellip;\n","protected":false},"author":2,"featured_media":80783,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[336,337,134,339],"class_list":["post-80782","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-biotechnology","tag-pharmaceuticals","tag-roche","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116726020430121272","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/80782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=80782"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/80782\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/80783"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=80782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=80782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=80782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}